Breaking News

Aduro Biotech Reaches Milestone

February 2, 2016

Gets $22.4mn in clinical development payments from Janssen

Aduro Biotech has received $22.4 million in clinical development milestone payments from Janssen Biotech, the company’s license partner for ADU-214, ADU-741 and other products using Aduro’s LADD technology platform for the treatment of specific cancers. Janssen is responsible for all clinical development for the product candidates within the license agreements.

“Our relationship with Janssen has been exceptionally productive, with ADU-214 for the treatment of lung cancer and ADU-741 for the treatment of prostate cancer advancing in clinical studies,” said Stephen Isaacs, chairman, president and chief executive officer, Aduro. “We believe these therapeutics may offer important alternatives for patients suffering from these aggressive cancers.”

In May 2014 and October 2014, Aduro entered into two separate agreements with Janssen, granting exclusive, worldwide licenses to ADU-741 and other product candidates engineered for the treatment of prostate cancer, and ADU-214 and other product candidates engineered for the treatment of lung cancer and certain other cancers, based on its novel LADD immunotherapy platform.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks